| Year |
Citation |
Score |
| 2023 |
Liu Y, John P, Nishitani K, Cui J, Nishimura CD, Christin JR, Couturier N, Ren X, Wei Y, Pulanco MC, Galbo PM, Zhang X, Fu W, Cui W, Bartholdy BA, ... ... Zang X, et al. A SOX9-B7x axis safeguards dedifferentiated tumor cells from immune surveillance to drive breast cancer progression. Developmental Cell. PMID 37963469 DOI: 10.1016/j.devcel.2023.10.010 |
0.429 |
|
| 2023 |
Pulanco MC, Madsen AT, Tanwar A, Corrigan DT, Zang X. Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies. Cellular & Molecular Immunology. PMID 37069229 DOI: 10.1038/s41423-023-01019-8 |
0.352 |
|
| 2022 |
Augustine T, John P, Friedman T, Jiffry J, Guzik H, Mannan R, Gupta R, Delano C, Mariadason JM, Zang X, Maitra R, Goel S. Potentiating effect of reovirus on immune checkpoint inhibition in microsatellite stable colorectal cancer. Frontiers in Oncology. 12: 1018767. PMID 36387154 DOI: 10.3389/fonc.2022.1018767 |
0.351 |
|
| 2022 |
Ren X, Corrigan DT, Zang X. Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model. Star Protocols. 3: 101818. PMID 36386885 DOI: 10.1016/j.xpro.2022.101818 |
0.322 |
|
| 2022 |
Ren X, Peng M, Xing P, Wei Y, Galbo PM, Corrigan D, Wang H, Su Y, Dong X, Sun Q, Li Y, Zhang X, Edelmann W, Zheng D, Zang X. Blockade of the immunosuppressive KIR2DL5/PVR pathway elicits potent human NK cell-mediated antitumor immunity. The Journal of Clinical Investigation. 132. PMID 36377656 DOI: 10.1172/JCI163620 |
0.353 |
|
| 2022 |
John P, Pulanco MC, Galbo PM, Wei Y, Ohaegbulam KC, Zheng D, Zang X. The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy. Nature Communications. 13: 2506. PMID 35523809 DOI: 10.1038/s41467-022-30143-8 |
0.417 |
|
| 2022 |
Picarda E, Galbo PM, Zong H, Rajan MR, Wallenius V, Zheng D, Börgeson E, Singh R, Pessin J, Zang X. The immune checkpoint B7-H3 (CD276) regulates adipocyte progenitor metabolism and obesity development. Science Advances. 8: eabm7012. PMID 35476450 DOI: 10.1126/sciadv.abm7012 |
0.319 |
|
| 2021 |
Ren X, Li Y, Nishimura C, Zang X. Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities. Genes & Diseases. 9: 1181-1193. PMID 35873032 DOI: 10.1016/j.gendis.2021.08.009 |
0.311 |
|
| 2021 |
Thakkar A, Cui Z, Peeke SZ, Shah N, Pradhan K, Lombardo A, Khatun F, Mustafa J, De Castro A, Gillick K, Joseph F, Naik A, Rahman S, D'Aiello A, Elkind R, ... ... Zang X, et al. Patterns of leukocyte recovery predict infectious complications after CD19 CAR-T cell therapy in a real-world setting. Stem Cell Investigation. 8: 18. PMID 34631871 DOI: 10.21037/sci-2021-008 |
0.321 |
|
| 2021 |
Zhou Q, Li K, Lai Y, Yao K, Wang Q, Zhan X, Peng S, Cai W, Yao W, Zang X, Xu K, Huang J, Huang H. B7 score and T cell infiltration stratify immune status in prostate cancer. Journal For Immunotherapy of Cancer. 9. PMID 34417325 DOI: 10.1136/jitc-2021-002455 |
0.325 |
|
| 2021 |
Wei Y, Ren X, Galbo PM, Moerdler S, Wang H, Sica RA, Etemad-Gilbertson B, Shi L, Zhu L, Tang X, Lin Q, Peng M, Guan F, Zheng D, Chinai JM, ... Zang X, et al. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Science Immunology. 6. PMID 34244312 DOI: 10.1126/sciimmunol.abf9792 |
0.447 |
|
| 2021 |
Zhang W, Acuna-Villaorduna A, Kuan K, Gupta S, Hu S, Ohaegbulam K, Albanese J, Kaumaya M, Levy R, Hwang RR, Zang X, Lin J, Liu Q, Maitra R, Goel S. B7-H3 and PD-L1 Expression Are Prognostic Biomarkers in a Multi-racial Cohort of Patients with Colorectal Cancer. Clinical Colorectal Cancer. PMID 33745842 DOI: 10.1016/j.clcc.2021.02.002 |
0.351 |
|
| 2021 |
Yuan Z, Gardiner JC, Maggi EC, Huang S, Adem A, Bagdasarov S, Li G, Lee S, Slegowski D, Exarchakis A, Howe JR, Lattime EC, Zang X, Libutti SK. B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors. Endocrine-Related Cancer. PMID 33410766 DOI: 10.1530/ERC-20-0337 |
0.472 |
|
| 2020 |
Nishimura CD, Pulanco MC, Cui W, Lu L, Zang X. PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies. Trends in Molecular Medicine. PMID 33199209 DOI: 10.1016/j.molmed.2020.10.004 |
0.318 |
|
| 2020 |
Moerdler S, Ewart M, Friedman DL, Kelly K, Pei Q, Peng M, Zang X, Cole PD. LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma. Leukemia & Lymphoma. 1-8. PMID 33112183 DOI: 10.1080/10428194.2020.1839651 |
0.332 |
|
| 2020 |
Li Y, Liu Y, Zhao N, Yang X, Li Y, Zhai F, Zang X, Cui W. Checkpoint regulator B7x is epigenetically regulated by HDAC3 and mediates resistance to HDAC inhibitors by reprogramming the tumor immune environment in colorectal cancer. Cell Death & Disease. 11: 753. PMID 32934224 DOI: 10.1038/S41419-020-02968-Y |
0.423 |
|
| 2020 |
Zhang Z, Liu J, Zhang C, Li F, Li L, Wang D, Chand D, Guan F, Zang X, Zhang Y. Over-Expression and Prognostic Significance of HHLA2, a New Immune Checkpoint Molecule, in Human Clear Cell Renal Cell Carcinoma. Frontiers in Cell and Developmental Biology. 8: 280. PMID 32509772 DOI: 10.3389/Fcell.2020.00280 |
0.455 |
|
| 2020 |
Moerdler S, Ewart M, Peng M, Zang X, Cole PD. LAG-3 overexpression in pediatric Hodgkin lymphoma. Journal of Clinical Oncology. 38: 10531-10531. DOI: 10.1200/Jco.2020.38.15_Suppl.10531 |
0.343 |
|
| 2020 |
Alexander M, Fan N, Ren X, Ross J, Wang H, Wang F, Halmos B, Perez-Soler R, Zang X, Cheng H. Abstract 1017: RICTOR/mTOR signaling regulates novel immune checkpoints in non-small cell lung cancer (NSCLC) Immunology. 80: 1017-1017. DOI: 10.1158/1538-7445.Am2020-1017 |
0.522 |
|
| 2019 |
John P, Wei Y, Liu W, Du M, Guan F, Zang X. The B7x Immune Checkpoint Pathway: From Discovery to Clinical Trial. Trends in Pharmacological Sciences. PMID 31677920 DOI: 10.1016/J.Tips.2019.09.008 |
0.459 |
|
| 2019 |
Liu W, Zang X. Structures of Immune Checkpoints: An Overview on the CD28-B7 Family. Advances in Experimental Medicine and Biology. 1172: 63-78. PMID 31628651 DOI: 10.1007/978-981-13-9367-9_3 |
0.431 |
|
| 2019 |
Saha A, Taylor PA, Lees CJ, Panoskaltsis-Mortari A, Osborn MJ, Feser CJ, Thangavelu G, Melchinger W, Refaeli Y, Hill GR, Munn DH, Murphy WJ, Serody JS, Maillard I, Kreymborg K, ... ... Zang X, et al. Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality. Jci Insight. 4. PMID 31578305 DOI: 10.1172/Jci.Insight.127716 |
0.48 |
|
| 2019 |
Rauch DA, Conlon KC, Janakiram M, Brammer JE, Harding JC, Ye BH, Zang X, Ren X, Olson S, Cheng X, Miljkovic MD, Sundaramoorthi H, Joseph A, Skidmore ZL, Griffith O, et al. . Blood. PMID 31467059 DOI: 10.1182/Blood.2019002038 |
0.456 |
|
| 2019 |
Cui Y, Zhang L, Wang W, Ma S, Liu H, Zang X, Zhang Y, Guan F. Downregulation of nicotinamide N-methyltransferase inhibits migration and epithelial-mesenchymal transition of esophageal squamous cell carcinoma via Wnt/β-catenin pathway. Molecular and Cellular Biochemistry. PMID 31278587 DOI: 10.1007/S11010-019-03573-0 |
0.351 |
|
| 2019 |
Picarda E, Ren X, Zang X. Tumor Cholesterol Up, T Cells Down. Cell Metabolism. 30: 12-13. PMID 31269422 DOI: 10.1016/J.Cmet.2019.06.007 |
0.42 |
|
| 2019 |
Huaman J, Naidoo M, Zang X, Ogunwobi OO. Fibronectin Regulation of Integrin B1 and SLUG in Circulating Tumor Cells. Cells. 8. PMID 31226820 DOI: 10.3390/cells8060618 |
0.335 |
|
| 2019 |
Wang H, Kaur G, Sankin AI, Chen F, Guan F, Zang X. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. Journal of Hematology & Oncology. 12: 59. PMID 31186046 DOI: 10.1186/S13045-019-0746-1 |
0.463 |
|
| 2019 |
Wang S, Sun F, Li M, Qian J, Chen C, Wang M, Zang X, Li D, Yu M, Du M. The appropriate frequency and function of decidual Tim-3CTLA-4CD8 T cells are important in maintaining normal pregnancy. Cell Death & Disease. 10: 407. PMID 31138782 DOI: 10.1038/S41419-019-1642-X |
0.44 |
|
| 2019 |
Ma S, Liu T, Xu L, Wang Y, Zhou J, Huang T, Li P, Liu H, Zhang Y, Zhou X, Cui Y, Zang X, Wang Y, Guan F. Histone deacetylases inhibitor MS-275 suppresses human esophageal squamous cell carcinoma cell growth and progression via the PI3K/Akt/mTOR pathway. Journal of Cellular Physiology. PMID 31120582 DOI: 10.1002/Jcp.28805 |
0.314 |
|
| 2019 |
Sankin A, Chand D, Schoenberg M, Zang X. Human urothelial bladder cancer generates a clonal immune response: The results of T-cell receptor sequencing. Urologic Oncology. PMID 31103336 DOI: 10.1016/J.Urolonc.2019.04.011 |
0.442 |
|
| 2019 |
Chung EYL, Mai Y, Shah UA, Wei Y, Ishida E, Kataoka K, Ren X, Pradhan K, Bartholdy B, Wei X, Zou Y, Zhang J, Ogawa S, Steidl U, Zang X, et al. PAK kinase inhibition has therapeutic activity in novel preclinical models of Adult T-cell Leukemia/Lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30862694 DOI: 10.1158/1078-0432.Ccr-18-3033 |
0.377 |
|
| 2019 |
Chand D, Dhawan D, Sankin A, Ren X, Lin J, Schoenberg M, Knapp DW, Zang X. Immune Checkpoint B7x (B7-H4/B7S1/VTCN1) is Over Expressed in Spontaneous Canine Bladder Cancer: The First Report and its Implications in a Preclinical Model. Bladder Cancer (Amsterdam, Netherlands). 5: 63-71. PMID 30854414 DOI: 10.3233/BLC-180204 |
0.323 |
|
| 2019 |
Li Y, Zhang D, Xu L, Dong L, Zheng J, Lin Y, Huang J, Zhang Y, Tao Y, Zang X, Li D, Du M. Cell-cell contact with proinflammatory macrophages enhances the immunotherapeutic effect of mesenchymal stem cells in two abortion models. Cellular & Molecular Immunology. PMID 30778166 DOI: 10.1038/S41423-019-0204-6 |
0.402 |
|
| 2019 |
Wang S, Chen C, Li M, Qian J, Sun F, Li Y, Yu M, Wang M, Zang X, Zhu R, Li D, Du M. Blockade of CTLA-4 and Tim-3 pathways induces fetal loss with altered cytokine profiles by decidual CD4T cells. Cell Death & Disease. 10: 15. PMID 30622243 DOI: 10.1038/S41419-018-1251-0 |
0.446 |
|
| 2019 |
Kaumaya M, Zhang W, Kuan K, Gupta S, Hu S, Rao D, Ohaegbulam K, Hwang R, Liu Q, Zang X, Goel S, Maitra R. B7-H3 expression by immunohistochemistry as a negative prognostic biomarker in colorectal carcinoma (CRC) in a racially diverse population. Journal of Clinical Oncology. 37: e15127-e15127. DOI: 10.1200/Jco.2019.37.15_Suppl.E15127 |
0.418 |
|
| 2019 |
Chinai JM, Wang H, Tang X, Janakiram M, Cheng H, Zang X. Abstract A180: HHLA2 is a novel tumor-expressed member of the B7 immune checkpoint family Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A180 |
0.527 |
|
| 2019 |
Pursnani S, Chand D, Dhawan D, Sankin A, Ren X, Lin J, Schoenberg M, Knapp DW, Zang X. Mp32-04 Immune Checkpoint B7X (B7-H4/B7S1/Vtcn1) Is Highly Expressed In Spontaneous Canine Bladder Cancer: The First Report And Its Implications In A Preclinical Model The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555856.86580.66 |
0.431 |
|
| 2018 |
Cheng H, Sharma J, Su C, Li S, Zang X, Perez-Soler R, Halmos B, Borczuk A. Differential expression of immune checkpoints (PD-L1, HHLA2, B7x and B7H3) and their association with driver mutations in pulmonary sarcomatoid carcinoma (PSC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii672. PMID 32137839 DOI: 10.1093/Annonc/Mdy304.005 |
0.339 |
|
| 2018 |
Zang X. 2018 Nobel Prize in medicine awarded to cancer immunotherapy: Immune checkpoint blockade - A personal account. Genes & Diseases. 5: 302-303. PMID 30591930 DOI: 10.1016/J.Gendis.2018.10.003 |
0.342 |
|
| 2018 |
Li L, Han L, Sun F, Zhou J, Ohaegbulam KC, Tang X, Zang X, Steinbrecher KA, Qu Z, Xiao G. NF-κB RelA renders tumor-associated macrophages resistant to and capable of directly suppressing CD8 T cells for tumor promotion. Oncoimmunology. 7: e1435250. PMID 29872577 DOI: 10.1080/2162402X.2018.1435250 |
0.486 |
|
| 2018 |
Ying L, Yan F, Meng Q, Yu L, Yuan X, Gantier MP, Williams BRG, Chan DW, Shi L, Tu Y, Ni P, Wang X, Chen W, Zang X, Xu D, et al. PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and FOXP3 immune markers. Oncoimmunology. 7: e1433520. PMID 29872566 DOI: 10.1080/2162402X.2018.1433520 |
0.473 |
|
| 2018 |
Cheng H, Borczuk A, Janakiram M, Ren X, Lin J, Assal A, Halmos B, Perez-Soler R, Zang X. Wide expression and significance of alternative immune checkpoint molecules, B7x and HHLA2, in PD-L1 negative human lung cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29374053 DOI: 10.1158/1078-0432.Ccr-17-2924 |
0.392 |
|
| 2018 |
Sankin A, Chand D, Schoenberg MP, Zang X. T-cell receptor sequencing of bladder tumor infiltrating lymphocytes to reveal a clonal immune response. Journal of Clinical Oncology. 36: 437-437. DOI: 10.1200/Jco.2018.36.6_Suppl.437 |
0.447 |
|
| 2018 |
Sankin A, Chand D, Schoenberg M, Zang X. MP58-14 USING T CELL RECEPTOR SEQUENCING TO CHARACTERIZE THE HOST IMMUNE RESPONSE IN UROTHELIAL CARCINOMA Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1846 |
0.38 |
|
| 2017 |
Ohaegbulam KC, Liu W, Jeon H, Almo SC, Zang X. Tumor-expressed immune checkpoint B7x promotes cancer progression and antigen-specific CD8 T cell exhaustion and suppressive innate immune cells. Oncotarget. 8: 82740-82753. PMID 29137299 DOI: 10.18632/Oncotarget.21098 |
0.553 |
|
| 2017 |
Sankin A, Narasimhulu D, John P, Gartrell B, Schoenberg M, Zang X. The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1. Urologic Oncology. PMID 28495553 DOI: 10.1016/J.Urolonc.2017.04.007 |
0.525 |
|
| 2017 |
McLemore LE, Janakiram M, Albanese J, Shapiro N, Lo Y, Zang X, Fineberg S. An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer. Applied Immunohistochemistry & Molecular Morphology : Aimm. PMID 28422766 DOI: 10.1097/Pai.0000000000000485 |
0.457 |
|
| 2017 |
Janakiram M, Shah UA, Liu W, Zhao A, Schoenberg MP, Zang X. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3. Immunological Reviews. 276: 26-39. PMID 28258693 DOI: 10.1111/Imr.12521 |
0.502 |
|
| 2017 |
Cheng H, Borczuk A, Janakiram M, Ren X, Lin J, Assal A, Halmos B, Perez-Soler R, Zang X. OA 13.03 Wide Expression of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1 Negative Human Lung Cancers Journal of Thoracic Oncology. 12: S1780. DOI: 10.1016/J.Jtho.2017.09.403 |
0.392 |
|
| 2017 |
Cheng H, Janakiram M, Borczuk A, Lin J, Qiu W, Liu H, Chinai J, Halmos B, Perez-Soler R, Zang X. OA20.07 HHLA2, a New Immune Checkpoint Member of the B7 Family, is Widely Expressed in Human Lung Cancer and Associated with Mutational Status Journal of Thoracic Oncology. 12: S325-S326. DOI: 10.1016/J.Jtho.2016.11.348 |
0.4 |
|
| 2016 |
Zhou TC, Sankin AI, Porcelli SA, Perlin DS, Schoenberg MP, Zang X. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment. Urologic Oncology. PMID 27816403 DOI: 10.1016/J.Urolonc.2016.10.004 |
0.406 |
|
| 2016 |
Cheng H, Janakiram M, Borczuk A, Lin J, Qiu W, Liu H, Chinai J, Halmos B, Perez-Soler R, Zang X. HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27553831 DOI: 10.1158/1078-0432.Ccr-15-3071 |
0.503 |
|
| 2016 |
Koirala P, Roth ME, Gill J, Chinai JM, Ewart MR, Piperdi S, Geller DS, Hoang BH, Fatakhova YV, Ghorpade M, Zang X, Gorlick R. HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival. Scientific Reports. 6: 31154. PMID 27531281 DOI: 10.1038/Srep31154 |
0.386 |
|
| 2016 |
Koirala P, Roth ME, Gill J, Piperdi S, Chinai JM, Geller DS, Hoang BH, Park A, Fremed MA, Zang X, Gorlick R. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Scientific Reports. 6: 30093. PMID 27456063 DOI: 10.1038/Srep30093 |
0.419 |
|
| 2016 |
Liu W, Almo SC, Zang X. Co-stimulate or Co-inhibit Regulatory T Cells, Which Side to Go? Immunological Investigations. 1-19. PMID 27419268 DOI: 10.1080/08820139.2016.1186690 |
0.45 |
|
| 2016 |
Janakiram M, Pareek V, Cheng H, Narasimhulu DM, Zang X. Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies. Immunotherapy. 8: 809-19. PMID 27349980 DOI: 10.2217/Imt-2016-0001 |
0.486 |
|
| 2016 |
Picarda E, Ohaegbulam KC, Zang X. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27208063 DOI: 10.1158/1078-0432.Ccr-15-2428 |
0.554 |
|
| 2016 |
Yao Y, Ye H, Qi Z, Mo L, Yue Q, Baral A, Hoon DS, Vera JC, Heiss JD, Chen CC, Hua W, Zhang J, Jin K, Wang Y, Zang X, et al. B7-H4(B7x)-Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27001312 DOI: 10.1158/1078-0432.Ccr-15-0858 |
0.41 |
|
| 2016 |
Koirala P, Roth M, Gill J, Chinai J, Piperdi S, Geller D, Hoang B, Poon V, Zang X, Gorlick R. Abstract 4134: Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma Cancer Research. 76: 4134-4134. DOI: 10.1158/1538-7445.Am2016-4134 |
0.418 |
|
| 2016 |
Koirala P, Roth M, Gill J, Chinai J, Ewart M, Piperdi S, Geller D, Hoang B, Fatakhova Y, Ghorpade M, Zang X, Gorlick R. Abstract 2221: HHLA2, a novel member of the B7 family of inhibitory ligands, is highly expressed in osteosarcoma Cancer Research. 76: 2221-2221. DOI: 10.1158/1538-7445.Am2016-2221 |
0.355 |
|
| 2015 |
Assal A, Kaner J, Pendurti G, Zang X. Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy. 7: 1169-86. PMID 26567614 DOI: 10.2217/Imt.15.78 |
0.444 |
|
| 2015 |
Janakiram M, Chinai JM, Zhao A, Sparano JA, Zang X. HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families. Oncoimmunology. 4: e1026534. PMID 26405587 DOI: 10.1080/2162402X.2015.1026534 |
0.403 |
|
| 2015 |
Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X. New immunotherapies targeting the PD-1 pathway. Trends in Pharmacological Sciences. 36: 587-95. PMID 26162965 DOI: 10.1016/J.Tips.2015.06.005 |
0.47 |
|
| 2015 |
Zhao H, Bauzon F, Bi E, Yu JJ, Fu H, Lu Z, Cui J, Jeon H, Zang X, Ye BH, Zhu L. Substituting threonine 187 with alanine in p27Kip1 prevents pituitary tumorigenesis by two-hit loss of Rb1 and enhances humoral immunity in old age. The Journal of Biological Chemistry. 290: 5797-809. PMID 25583987 DOI: 10.1074/Jbc.M114.625350 |
0.475 |
|
| 2015 |
Janakiram M, Chinai JM, Fineberg S, Fiser A, Montagna C, Medavarapu R, Castano E, Jeon H, Ohaegbulam KC, Zhao R, Zhao A, Almo SC, Sparano JA, Zang X. Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2359-66. PMID 25549724 DOI: 10.1158/1078-0432.Ccr-14-1495 |
0.438 |
|
| 2015 |
Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends in Molecular Medicine. 21: 24-33. PMID 25440090 DOI: 10.1016/J.Molmed.2014.10.009 |
0.425 |
|
| 2015 |
Pawar RD, Goilav B, Xia Y, Herlitz L, Doerner J, Chalmers S, Ghosh K, Zang X, Putterman C. B7x/B7-H4 modulates the adaptive immune response and ameliorates renal injury in antibody-mediated nephritis. Clinical and Experimental Immunology. 179: 329-43. PMID 25205493 DOI: 10.1111/Cei.12452 |
0.422 |
|
| 2014 |
Jeon H, Vigdorovich V, Garrett-Thomson SC, Janakiram M, Ramagopal UA, Abadi YM, Lee JS, Scandiuzzi L, Ohaegbulam KC, Chinai JM, Zhao R, Yao Y, Mao Y, Sparano JA, Almo SC, ... Zang X, et al. Structure and cancer immunotherapy of the B7 family member B7x. Cell Reports. 9: 1089-98. PMID 25437562 DOI: 10.1016/J.Celrep.2014.09.053 |
0.796 |
|
| 2014 |
Scandiuzzi L, Ghosh K, Hofmeyer KA, Abadi YM, Lázár-Molnár E, Lin EY, Liu Q, Jeon H, Almo SC, Chen L, Nathenson SG, Zang X. Tissue-expressed B7-H1 critically controls intestinal inflammation. Cell Reports. 6: 625-32. PMID 24529703 DOI: 10.1016/J.Celrep.2014.01.020 |
0.754 |
|
| 2013 |
Singh M, Ramos I, Asafu-Adjei D, Quispe-Tintaya W, Chandra D, Jahangir A, Zang X, Aggarwal BB, Gravekamp C. Curcumin improves the therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1. Cancer Medicine. 2: 571-82. PMID 24156030 DOI: 10.1002/Cam4.94 |
0.451 |
|
| 2013 |
Jeon H, Ohaegbulam KC, Abadi YM, Zang X. B7x and myeloid-derived suppressor cells in the tumor microenvironment: A tale of two cities. Oncoimmunology. 2: e24744. PMID 24073367 DOI: 10.4161/Onci.24744 |
0.759 |
|
| 2013 |
Zhao R, Chinai JM, Buhl S, Scandiuzzi L, Ray A, Jeon H, Ohaegbulam KC, Ghosh K, Zhao A, Scharff MD, Zang X. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proceedings of the National Academy of Sciences of the United States of America. 110: 9879-84. PMID 23716685 DOI: 10.1073/Pnas.1303524110 |
0.507 |
|
| 2013 |
Vigdorovich V, Ramagopal UA, Lázár-Molnár E, Sylvestre E, Lee JS, Hofmeyer KA, Zang X, Nathenson SG, Almo SC. Structure and T cell inhibition properties of B7 family member, B7-H3. Structure (London, England : 1993). 21: 707-17. PMID 23583036 DOI: 10.1016/J.Str.2013.03.003 |
0.784 |
|
| 2013 |
Abadi YM, Jeon H, Ohaegbulam KC, Scandiuzzi L, Ghosh K, Hofmeyer KA, Lee JS, Ray A, Gravekamp C, Zang X. Host b7x promotes pulmonary metastasis of breast cancer. Journal of Immunology (Baltimore, Md. : 1950). 190: 3806-14. PMID 23455497 DOI: 10.4049/Jimmunol.1202439 |
0.77 |
|
| 2012 |
Janakiram M, Abadi YM, Sparano JA, Zang X. T cell coinhibition and immunotherapy in human breast cancer. Discovery Medicine. 14: 229-36. PMID 23114578 |
0.806 |
|
| 2012 |
Lee JS, Scandiuzzi L, Ray A, Wei J, Hofmeyer KA, Abadi YM, Loke P, Lin J, Yuan J, Serreze DV, Allison JP, Zang X. B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cells. Journal of Immunology (Baltimore, Md. : 1950). 189: 4165-74. PMID 22972920 DOI: 10.4049/Jimmunol.1201241 |
0.751 |
|
| 2012 |
Hofmeyer KA, Scandiuzzi L, Ghosh K, Pirofski LA, Zang X. Tissue-expressed B7x affects the immune response to and outcome of lethal pulmonary infection. Journal of Immunology (Baltimore, Md. : 1950). 189: 3054-63. PMID 22855708 DOI: 10.4049/Jimmunol.1200701 |
0.777 |
|
| 2011 |
Hofmeyer KA, Jeon H, Zang X. The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion. Journal of Biomedicine & Biotechnology. 2011: 451694. PMID 21960736 DOI: 10.1155/2011/451694 |
0.758 |
|
| 2011 |
Scandiuzzi L, Ghosh K, Zang X. T cell costimulation and coinhibition: genetics and disease. Discovery Medicine. 12: 119-28. PMID 21878189 |
0.318 |
|
| 2011 |
Wei J, Loke P, Zang X, Allison JP. Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity. The Journal of Experimental Medicine. 208: 1683-94. PMID 21727190 DOI: 10.1084/Jem.20100639 |
0.49 |
|
| 2011 |
Barach YS, Lee JS, Zang X. T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics. Trends in Molecular Medicine. 17: 47-55. PMID 20971039 DOI: 10.1016/J.Molmed.2010.09.006 |
0.551 |
|
| 2010 |
Scandiuzzi L, Beghdadi W, Daugas E, Abrink M, Tiwari N, Brochetta C, Claver J, Arouche N, Zang X, Pretolani M, Monteiro RC, Pejler G, Blank U. Mouse mast cell protease-4 deteriorates renal function by contributing to inflammation and fibrosis in immune complex-mediated glomerulonephritis. Journal of Immunology (Baltimore, Md. : 1950). 185: 624-33. PMID 20530261 DOI: 10.4049/Jimmunol.0902129 |
0.372 |
|
| 2010 |
Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, Wilton A, Thaler HT, Arul M, Slovin SF, Wei J, Spriggs DR, Dupont J, Allison JP. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 23: 1104-12. PMID 20495537 DOI: 10.1038/Modpathol.2010.95 |
0.441 |
|
| 2008 |
Thompson RH, Zang X, Lohse CM, Leibovich BC, Slovin SF, Reuter VE, Blute ML, Russo P, Kwon ED, Allison JP. Evaluation of soluble B7x as a serum marker in patients with clear cell renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5052. PMID 27948878 DOI: 10.1200/Jco.2008.26.15_Suppl.5052 |
0.392 |
|
| 2008 |
Thompson RH, Zang X, Lohse CM, Leibovich BC, Slovin SF, Reuter VE, Cheville JC, Blute ML, Russo P, Kwon ED, Allison JP. Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Research. 68: 6054-8. PMID 18676826 DOI: 10.1158/0008-5472.Can-08-0869 |
0.358 |
|
| 2008 |
Hofmeyer KA, Ray A, Zang X. The contrasting role of B7-H3. Proceedings of the National Academy of Sciences of the United States of America. 105: 10277-8. PMID 18650376 DOI: 10.1073/Pnas.0805458105 |
0.789 |
|
| 2007 |
Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, Scardino PT, Sharma P, Allison JP. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proceedings of the National Academy of Sciences of the United States of America. 104: 19458-63. PMID 18042703 DOI: 10.1073/Pnas.0709802104 |
0.458 |
|
| 2007 |
Zang X, Allison JP. The B7 family and cancer therapy: costimulation and coinhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5271-9. PMID 17875755 DOI: 10.1158/1078-0432.Ccr-07-1030 |
0.538 |
|
| 2007 |
Loke P, Gallagher I, Nair MG, Zang X, Brombacher F, Mohrs M, Allison JP, Allen JE. Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection. Journal of Immunology (Baltimore, Md. : 1950). 179: 3926-36. PMID 17785830 DOI: 10.4049/Jimmunol.179.6.3926 |
0.408 |
|
| 2007 |
Cao E, Zang X, Ramagopal UA, Mukhopadhaya A, Fedorov A, Fedorov E, Zencheck WD, Lary JW, Cole JL, Deng H, Xiao H, Dilorenzo TP, Allison JP, Nathenson SG, Almo SC. T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. Immunity. 26: 311-21. PMID 17363302 DOI: 10.1016/J.Immuni.2007.01.016 |
0.426 |
|
| 2006 |
Zang X, Allison JP. To be or not to be B7. The Journal of Clinical Investigation. 116: 2590-3. PMID 17016555 DOI: 10.1172/Jci30103 |
0.432 |
|
| 2006 |
Zang X, Loke P, Kim J, Wojnoonski K, Kusdra L, Allison JP. A genetic library screen for signaling proteins that interact with phosphorylated T cell costimulatory receptors. Genomics. 88: 841-5. PMID 17014982 DOI: 10.1016/J.Ygeno.2006.08.012 |
0.382 |
|
| 2005 |
Loke P, Zang X, Hsuan L, Waitz R, Locksley RM, Allen JE, Allison JP. Inducible costimulator is required for type 2 antibody isotype switching but not T helper cell type 2 responses in chronic nematode infection. Proceedings of the National Academy of Sciences of the United States of America. 102: 9872-7. PMID 15994233 DOI: 10.1073/Pnas.0503961102 |
0.421 |
|
| 2003 |
Zang X, Loke P, Kim J, Murphy K, Waitz R, Allison JP. B7x: a widely expressed B7 family member that inhibits T cell activation. Proceedings of the National Academy of Sciences of the United States of America. 100: 10388-92. PMID 12920180 DOI: 10.1073/Pnas.1434299100 |
0.54 |
|
| 2003 |
Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, Murphy TL, Russell JH, Allison JP, Murphy KM. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nature Immunology. 4: 670-9. PMID 12796776 DOI: 10.1038/Ni944 |
0.486 |
|
| 2002 |
Zang X, Taylor P, Wang JM, Meyer DJ, Scott AL, Walkinshaw MD, Maizels RM. Homologues of human macrophage migration inhibitory factor from a parasitic nematode. Gene cloning, protein activity, and crystal structure. The Journal of Biological Chemistry. 277: 44261-7. PMID 12221083 DOI: 10.1074/Jbc.M204655200 |
0.315 |
|
| 2001 |
Falcone FH, Loke P, Zang X, MacDonald AS, Maizels RM, Allen JE. A Brugia malayi homolog of macrophage migration inhibitory factor reveals an important link between macrophages and eosinophil recruitment during nematode infection. Journal of Immunology (Baltimore, Md. : 1950). 167: 5348-54. PMID 11673551 DOI: 10.4049/Jimmunol.167.9.5348 |
0.354 |
|
| 2001 |
Maizels RM, Gomez-Escobar N, Gregory WF, Murray J, Zang X. Immune evasion genes from filarial nematodes. International Journal For Parasitology. 31: 889-98. PMID 11406138 DOI: 10.1016/S0020-7519(01)00213-2 |
0.387 |
|
| 2000 |
Zang X, Atmadja AK, Gray P, Allen JE, Gray CA, Lawrence RA, Yazdanbakhsh M, Maizels RM. The serpin secreted by Brugia malayi microfilariae, Bm-SPN-2, elicits strong, but short-lived, immune responses in mice and humans Journal of Immunology. 165: 5161-5169. PMID 11046048 DOI: 10.4049/Jimmunol.165.9.5161 |
0.43 |
|
| 1999 |
Zang X, Yazdanbakhsh M, Jiang H, Kanost MR, Maizels RM. A Novel Serpin Expressed by Blood-Borne Microfilariae of the Parasitic Nematode Brugia malayi Inhibits Human Neutrophil Serine Proteinases Blood. 94: 1418-1428. DOI: 10.1182/Blood.V94.4.1418.416K03_1418_1428 |
0.322 |
|
| Show low-probability matches. |